Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

Lifespan25 enrolled

Overview

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Opioid Use Disorder Criminal Justice Treatment Adherence and Compliance

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Incarcerated individuals, inclusion criteria: * English speaking * Over the age of 18 * Diagnosed with opioid use disorder Incarcerated individuals, Exclusion Criteria: \- Diagnosed with "Severe, Persistent, Mental Illness (SPMI)" Rationale for Exclusion: These individuals suffer from severe mental health disease and therefore warrant greater protection, have greater risk for coercion, and offer insights to severe co-diagnosis treatment that, while important, remain outside the scope of general MAT implementation. Organizational Stakeholders, Inclusion Criteria: \- Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program Organizational Stakeholders, Exclusion Criteria: \- If not permitted by their organizational union to participate

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts